CORT · earnings call history
Corcept Therapeutics Q2 FY26 — Strong Lifyorli Launch and Increased Full-Year Guidance
Read the briefCorcept Therapeutics Q1 FY26 — Strong Growth in Endocrinology and Successful Lifyorli Launch Drive Raised Guidance
Read the briefCorcept Therapeutics Q4 FY25 — Strong Korlym Growth Offset by Relacorilant CRL, Oncology Pipeline Progresses
Read the briefBrowse all US companies on the earnings-call register.